Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK.
J Clin Psychopharmacol. 2013 Jun;33(3):329-35. doi: 10.1097/JCP.0b013e31828b28d5.
To conduct a systematic review examining the relationships between olanzapine dose, clinical outcome, dopamine occupancy, and plasma concentration; and to evaluate the potential for therapeutic drug monitoring.
A search using Embase, Medline, and Pubmed was conducted; and the literature was systematically reviewed. Studies meeting inclusion criteria were examined. The relationships between olanzapine dose, response, dopamine occupancy, and concentration were analyzed using statistical regression.
Ten studies were included in the analysis for dose-response. The effect size-dose relationship showed a typical dose-response curve with minimal rise in slope for doses higher than 10 mg/d. For the dose-occupancy relationship, 6 studies were included. Doses more than approximately 12 mg/d were sufficient to block 65% of striatal D2 receptors. Doses higher than 20 mg led to minimally higher receptor occupancies. Fifteen studies were included in the meta-regression of olanzapine mean concentrations. A linear relationship between mean plasma concentration and mean dose was observed.
Our review suggests that the likelihood of a favorable response with olanzapine is maximized at doses of 10 to 15 mg/d (perhaps lower in nonsmoking females). Higher doses may be considered if 15 mg is ineffective and if plasma level is less than 20 ng/mL on that dose. There is a direct linear relationship between olanzapine dose and plasma concentration. Therapeutic drug monitoring may be useful in patients who are suspected of nonadherence, where there is potential for a drug interaction, and in patients taking 15 mg/d or more and who have not reached clinical response.
系统评价奥氮平剂量、临床疗效、多巴胺占有率和血浆浓度之间的关系,并评估治疗药物监测的潜力。
使用 Embase、Medline 和 Pubmed 进行搜索,并对文献进行系统回顾。检查符合纳入标准的研究。使用统计回归分析奥氮平剂量、反应、多巴胺占有率和浓度之间的关系。
10 项研究被纳入剂量-反应分析。效应大小-剂量关系显示出典型的剂量-反应曲线,高于 10mg/d 的剂量斜率增加最小。对于剂量-占有率关系,纳入了 6 项研究。超过约 12mg/d 的剂量足以阻断 65%的纹状体 D2 受体。剂量高于 20mg 会导致受体占有率略有升高。15 项研究被纳入奥氮平平均浓度的荟萃回归分析。观察到平均血浆浓度与平均剂量之间存在线性关系。
我们的综述表明,奥氮平的疗效最大可能发生在 10 至 15mg/d 的剂量(非吸烟女性可能更低)。如果 15mg 无效,如果该剂量下的血浆水平低于 20ng/ml,则可以考虑更高的剂量。奥氮平剂量与血浆浓度之间存在直接的线性关系。治疗药物监测可能对疑似不依从的患者、有药物相互作用的患者以及服用 15mg/d 或更高剂量且未达到临床反应的患者有用。